PsCas9 使

Dmitrii Degtev1, Jack Bravo2, Aikaterini Emmanouilidi3

  • 1Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Gothenburg, Sweden. dmitrii.degtev@astrazeneca.com.

Nature communications
|November 7, 2024
PubMed
概括

工程PsCas9 (ePsCas9) 提高了CRISPR-Cas9基因组编辑效率和安全性,用于体内应用. 这一突破使得精确的基因疗法能够针对诸如高胆固醇血症等疾病.